Skip to main content
ADCES 2026 Annual Conference Main banner

Technology Integration

(S08) International Consensus Recommendations for Leveraging CGM and AID During Pregnancy

Saturday, August 8, 2026
10:40 AM - 11:25 AM ET
CE: .75 CE
Pregnancy requires particularly careful diabetes management, which can necessitate new strategies and additional support. Emerging evidence shows promise for use of automated insulin delivery (AID) and continuous glucose monitoring (CGM) to support management and outcomes, but product approvals and clinical guidance have lagged, creating uncertainty for use during this life stage. This session will provide critical updates from the new international expert consensus for the use of AID and CGM in pregnant individuals with T1D, T2D, or GDM published in 2026, including varying CGM targets for each type of diabetes and how to support people with diabetes in selecting, initiating, or adapting AID systems to best fit pregnancy needs.

Learning Objectives:

At the completion of this activity, participants should be able to:
  • Explain differences in recommendations for CGM use and TIR goals in pregnancy with T1D, T2D, and gestational diabetes.
  • Describe nuanced differences between AID devices and identify those best suited for use in pregnancy.
  • Apply recommended strategies to optimize AID system settings for pregnancy-specific needs
Disclosure(s):
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP: Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)
Mareda Lewer, MPH: No financial relationships to disclose

    Primary Presenter(s)

  • Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP (she/her/hers)

    Endocrine Clinical Pharmacy Specialist
    Cleveland Clinic Endocrinology & Metabolism Institute

    Disclosure(s): Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)

    • Co-Presenter(s)

  • ML

    Mareda Lewer, MPH

    Research and Regulator Manager
    The diaTribe Foundation

    Disclosure(s): No financial relationships to disclose